ReviewClinical obstetrics and gynecology2008
Postmenopausal hormone therapy and cardiovascular disease in perspective.
Review in Clinical obstetrics and gynecology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 43 citations in OpenAlex.
- Alterations in platelet function and cell-derived microvesicles in recently menopausal women: relationship to metabolic syndrome and atherogenic risk.Journal of cardiovascular translational research · 2011Trial
- Using basic science to design a clinical trial: baseline characteristics of women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS).Journal of cardiovascular translational research · 2009Trial
- Association of Current and Long-Term Estradiol Use with Carotid Intima Media Thickness Among Transgender Women: A Cross-Sectional Study.Transgender health · 2024Article
- Toward a Value-Based Therapy Recommendation Model.Healthcare (Basel, Switzerland) · 2023Article
- Changes in carotid artery intima-media thickness 3 years after cessation of menopausal hormone therapy: follow-up from the Kronos Early Estrogen Prevention Study.Menopause (New York, N.Y.) · 2019Article
- Associations of adversity in childhood and risk factors for cardiovascular disease in mid-adulthood.Child abuse & neglect · 2018Article
- The timing hypothesis for coronary heart disease prevention with hormone therapy: past, present and future in perspective.Climacteric : the journal of the International Menopause Society · 2012Article
- Physical activity, hormone replacement therapy, and the presence of coronary calcium in midlife women.Women & health · 2012Article
- Implications for reproductive medicine: Sex differences in cardiovascular disease.Sexuality, reproduction & menopause · 2011Article
- A "window of opportunity:" the reduction of coronary heart disease and total mortality with menopausal therapies is age- and time-dependent.Brain research · 2011Review
- Article
- Influence of age and obesity on serum estradiol, estrone, and sex hormone binding globulin concentrations following oral estrogen administration in postmenopausal women.The Journal of clinical endocrinology and metabolism · 2009Article
- Sex/gender medicine. The biological basis for personalized care in cardiovascular medicine.Circulation journal : official journal of the Japanese Circulation Society · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The totality of data indicate that the window of opportunity for reducing mortality and coronary heart disease is initiation of hormone therapy (HT) within 6 years of menopause and/or by 60 years of age and continued for 6 years or more. Additionally, the risks of HT are rare (<1/1000) especially in younger postmenopausal women and comparable with other primary prevention therapies. In fact, as randomized controlled trial results accumulate, the more they look like the consistent observational data. These studies showed that young postmenopausal women with menopausal symptoms who use HT for long periods of time have lower rates of mortality and coronary heart disease than comparable postmenopausal women who do not use HT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.